174 related articles for article (PubMed ID: 38359967)
21. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal.
Yu S; Zhang C; Xie KP
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188461. PubMed ID: 33157162
[TBL] [Abstract][Full Text] [Related]
22. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
23. Stroma-targeting strategies in pancreatic cancer: Past lessons, challenges and prospects.
Polani F; Grierson PM; Lim KH
World J Gastroenterol; 2021 May; 27(18):2105-2121. PubMed ID: 34025067
[TBL] [Abstract][Full Text] [Related]
24. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
25. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
26. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic targeting DNMT1 of pancreatic ductal adenocarcinoma using interstitial control release biodegrading polymer reduced tumor growth through hedgehog pathway inhibition.
Huang MH; Chou YW; Li MH; Shih TE; Lin SZ; Chuang HM; Chiou TW; Su HL; Harn HJ
Pharmacol Res; 2019 Jan; 139():50-61. PubMed ID: 30385365
[TBL] [Abstract][Full Text] [Related]
28. Tumor heterogeneity: An oncogenic driver of PDAC progression and therapy resistance under stress conditions.
Palma AM; Vudatha V; Peixoto ML; Madan E
Adv Cancer Res; 2023; 159():203-249. PubMed ID: 37268397
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic ductal adenocarcinoma: tumor microenvironment and problems in the development of novel therapeutic strategies.
Kuznetsova A; Popova O; Panchenkov D; Dyuzheva T; Ivanov A
Clin Exp Med; 2023 Jul; 23(3):619-643. PubMed ID: 36085429
[TBL] [Abstract][Full Text] [Related]
30. Synergistic blocking of RAS downstream signaling and epigenetic pathway in
Zhang X; Mao T; Xu H; Li S; Yue M; Ma J; Yao J; Wang Y; Zhang X; Ge W; Wang Y; Shentu D; Wang L
Aging (Albany NY); 2022 Apr; 14(8):3597-3606. PubMed ID: 35468095
[TBL] [Abstract][Full Text] [Related]
31. Novel systemic treatment approaches for metastatic pancreatic cancer.
Dorman K; Heinemann V; Kobold S; von Bergwelt-Baildon M; Boeck S
Expert Opin Investig Drugs; 2022 Mar; 31(3):249-262. PubMed ID: 35114868
[TBL] [Abstract][Full Text] [Related]
32. Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment.
Wood LD; Canto MI; Jaffee EM; Simeone DM
Gastroenterology; 2022 Aug; 163(2):386-402.e1. PubMed ID: 35398344
[TBL] [Abstract][Full Text] [Related]
33. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma.
Ng CF; Glaspy J; Placencio-Hickok VR; Thomassian S; Gong J; Osipov A; Hendifar AE; Moshayedi N
J Natl Compr Canc Netw; 2022 Oct; 20(10):1076-1079. PubMed ID: 36240849
[TBL] [Abstract][Full Text] [Related]
34. Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma.
Xu R; Xu Q; Huang G; Yin X; Zhu J; Peng Y; Song J
Biomed Res Int; 2019; 2019():9379864. PubMed ID: 31956659
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in Pancreatic Ductal Adenocarcinoma (PDAC) Models.
Miao T; Symonds A; Hickman OJ; Wu D; Wang P; Lemoine N; Wang Y; Linardopoulos S; Halldén G
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279262
[TBL] [Abstract][Full Text] [Related]
36. KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy.
Gurreri E; Genovese G; Perelli L; Agostini A; Piro G; Carbone C; Tortora G
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298264
[TBL] [Abstract][Full Text] [Related]
37. Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Bhoopathi P; Mannangatti P; Das SK; Fisher PB; Emdad L
Adv Cancer Res; 2023; 159():285-341. PubMed ID: 37268399
[TBL] [Abstract][Full Text] [Related]
38. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
39. Identifying a baicalein-related prognostic signature contributes to prognosis prediction and tumor microenvironment of pancreatic cancer.
Zhang C; Lei D; Zhou Y; Zhong T; Li X; Ai W; Zheng B; Liu J; Piao Y; Yan Z; Lai Z
Front Immunol; 2023; 14():1223650. PubMed ID: 37575248
[TBL] [Abstract][Full Text] [Related]
40. [Metastasis of pancreatic tumors].
Häberle L; Braren R; Schlitter AM; Esposito I
Pathologe; 2015 Nov; 36 Suppl 2():176-80. PubMed ID: 26391249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
